Changing the Treatment of Permanent Neonatal Diabetes Mellitus from Insulin to Glibenclamide in a 4-Month-Old Infant with KCNJ11 Activating Mutation

Permanent neonatal diabetes mellitus (PNDM) is a rare type of diabetes and KCNJ11 gene activating mutation is one of its prevalent causes. We introduced a 4-month-old male infant with poor feeding, restlessness, tachypnea, hyperglycemia, metabolic acidosis, and ketonemia. He was discharged with insu...

Descripción completa

Detalles Bibliográficos
Autores principales: Ilkhanipoor, Homa, Karamizadeh, Zohreh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2013
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3793492/
https://www.ncbi.nlm.nih.gov/pubmed/24130952
_version_ 1782477825215823872
author Ilkhanipoor, Homa
Karamizadeh, Zohreh
author_facet Ilkhanipoor, Homa
Karamizadeh, Zohreh
author_sort Ilkhanipoor, Homa
collection PubMed
description Permanent neonatal diabetes mellitus (PNDM) is a rare type of diabetes and KCNJ11 gene activating mutation is one of its prevalent causes. We introduced a 4-month-old male infant with poor feeding, restlessness, tachypnea, hyperglycemia, metabolic acidosis, and ketonemia. He was discharged with insulin and after 2 months, KCNJ11 gene mutation was found and treatment was switched from subcutaneous insulin to oral glibenclamide. Now, he is 1 year old with desirable glycemic control; therefore, genetic study is recommended for KCNJ11 gene mutation in such patients because if the mutation is found, treatment can be switched from insulin to sulfonylurea.
format Online
Article
Text
id pubmed-3793492
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-37934922013-10-15 Changing the Treatment of Permanent Neonatal Diabetes Mellitus from Insulin to Glibenclamide in a 4-Month-Old Infant with KCNJ11 Activating Mutation Ilkhanipoor, Homa Karamizadeh, Zohreh Int J Prev Med Case Report Permanent neonatal diabetes mellitus (PNDM) is a rare type of diabetes and KCNJ11 gene activating mutation is one of its prevalent causes. We introduced a 4-month-old male infant with poor feeding, restlessness, tachypnea, hyperglycemia, metabolic acidosis, and ketonemia. He was discharged with insulin and after 2 months, KCNJ11 gene mutation was found and treatment was switched from subcutaneous insulin to oral glibenclamide. Now, he is 1 year old with desirable glycemic control; therefore, genetic study is recommended for KCNJ11 gene mutation in such patients because if the mutation is found, treatment can be switched from insulin to sulfonylurea. Medknow Publications & Media Pvt Ltd 2013-09 /pmc/articles/PMC3793492/ /pubmed/24130952 Text en Copyright: © International Journal of Preventive Medicine http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Ilkhanipoor, Homa
Karamizadeh, Zohreh
Changing the Treatment of Permanent Neonatal Diabetes Mellitus from Insulin to Glibenclamide in a 4-Month-Old Infant with KCNJ11 Activating Mutation
title Changing the Treatment of Permanent Neonatal Diabetes Mellitus from Insulin to Glibenclamide in a 4-Month-Old Infant with KCNJ11 Activating Mutation
title_full Changing the Treatment of Permanent Neonatal Diabetes Mellitus from Insulin to Glibenclamide in a 4-Month-Old Infant with KCNJ11 Activating Mutation
title_fullStr Changing the Treatment of Permanent Neonatal Diabetes Mellitus from Insulin to Glibenclamide in a 4-Month-Old Infant with KCNJ11 Activating Mutation
title_full_unstemmed Changing the Treatment of Permanent Neonatal Diabetes Mellitus from Insulin to Glibenclamide in a 4-Month-Old Infant with KCNJ11 Activating Mutation
title_short Changing the Treatment of Permanent Neonatal Diabetes Mellitus from Insulin to Glibenclamide in a 4-Month-Old Infant with KCNJ11 Activating Mutation
title_sort changing the treatment of permanent neonatal diabetes mellitus from insulin to glibenclamide in a 4-month-old infant with kcnj11 activating mutation
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3793492/
https://www.ncbi.nlm.nih.gov/pubmed/24130952
work_keys_str_mv AT ilkhanipoorhoma changingthetreatmentofpermanentneonataldiabetesmellitusfrominsulintoglibenclamideina4montholdinfantwithkcnj11activatingmutation
AT karamizadehzohreh changingthetreatmentofpermanentneonataldiabetesmellitusfrominsulintoglibenclamideina4montholdinfantwithkcnj11activatingmutation

Ejemplares similares